PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

Background Patients with advanced rare cancers have poor prognosis and few treatment
options. As immunotherapy is effective across multiple cancer types, we aimed to assess …

Purpose: To evaluate cMET (mesenchymal–epithelial transition factor gene) and phospho-
cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes …

Importance Appendiceal adenocarcinoma is a rare tumor, and given the inherent difficulties
in performing prospective trials in such a rare disease, there are currently minimal high …

PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor
(EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of …

Objective: To evaluate the association of perioperative ctDNA dynamics on outcomes after
hepatectomy for CLM. Summary Background Data: Prognostication is imprecise for patients …

Background Fibrolamellar carcinoma (FLC) and conventional hepatocellular carcinoma
(HCC) share the same American Joint Committee on Cancer (AJCC) staging. The worse …

Background Cancer of unknown primary (CUP) is an aggressive rare malignancy with
limited treatment options. Data regarding clinical activity of immune checkpoint inhibitors in …

BACKGROUND Treatment methods for intrahepatic cholangiocarcinoma (ICC) have
improved, but their impact on outcome remains unclear. We evaluated the outcomes of …

Background Moderately and poorly differentiated adenocarcinoma of the appendix
represents an aggressive histological variant with a high risk of recurrence and death …